Literature DB >> 7925564

T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells.

S Vollmer1, A Menssen, P Trommler, D Schendel, J C Prinz.   

Abstract

In various immunological disorders the pathomechanisms of tissue damage are causally associated with specific patterns of locally produced cytokines. To study the molecular and cellular mechanisms involved in the manifestation of psoriasis vulgaris we have assessed the cytokine mRNA profile expressed in lesional psoriatic skin and in T cell clones (TCC) that were established from skin lesions of patients with psoriasis. As demonstrated by use of the polymerase chain reaction (PCR), psoriasis lesions consistently exhibit transcription of a complex pattern of cytokines. It includes mediators selectively produced by T lymphocytes [interferon (IFN)-gamma, tumor necrosis factor (TNF)-beta, interleukin (IL)-2, IL-3 and IL-5] as well as cytokines secreted by various cell types [transforming growth factor (TGF)-alpha/-beta, TNF-alpha, IL-6/-8 and granulocyte-macrophage-colony stimulating factor], while IL-4 is missing. With the exception of TGF-alpha, this cytokine profile was also observed in lesional psoriatic T cell clones yielding supernatants mitogenic for keratinocytes in vitro (MTCC), but not in T cell clones yielding supernatants that inhibited keratinocyte proliferation (STCC). The congruent cytokine expression of psoriatic skin lesions and MTCC emphasizes that inflammation in psoriasis is driven by a sofar unrecognized regulatory T cell subset that may serve to control epidermal regeneration and convey immunosurveillance over epithelial surfaces. It is characterized by the combined expression of IFN-gamma, TGF-beta, IL-2 and IL-5 in the absence of IL-4 and by its selective capacity to enhance keratinocyte proliferation. This newly defined combination of regulatory properties of a distinct T cell population cannot be reconciled with an immune response of the T helper cells (TH)0, TH1 or TH2 type.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7925564     DOI: 10.1002/eji.1830241018

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

1.  Reduced IFN-gamma responses associated with HLA-DR15 presentation of streptococcal cell wall proteins to dermal Th-1 cells in psoriasis.

Authors:  Barbara S Baker; Jean-Marc Ovigne; Vincent A Fischetti; Anne Powles; Lionel Fry
Journal:  J Clin Immunol       Date:  2003-09       Impact factor: 8.317

2.  Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation.

Authors:  Hideaki Sugiyama; Rolland Gyulai; Eiko Toichi; Edina Garaczi; Shinji Shimada; Seth R Stevens; Thomas S McCormick; Kevin D Cooper
Journal:  J Immunol       Date:  2005-01-01       Impact factor: 5.422

Review 3.  Cytokines in psoriasis.

Authors:  Jaymie Baliwag; Drew H Barnes; Andrew Johnston
Journal:  Cytokine       Date:  2015-01-10       Impact factor: 3.861

4.  Interferon-gamma-dependent stimulation of human involucrin gene expression: STAT1 (signal transduction and activators of transcription 1) protein activates involucrin promoter activity.

Authors:  H Takahashi; K Asano; S Nakamura; A Ishida-Yamamoto; H Iizuka
Journal:  Biochem J       Date:  1999-12-15       Impact factor: 3.857

5.  Alternatively activated macrophages actively inhibit proliferation of peripheral blood lymphocytes and CD4+ T cells in vitro.

Authors:  C Schebesch; V Kodelja; C Müller; N Hakij; S Bisson; C E Orfanos; S Goerdt
Journal:  Immunology       Date:  1997-12       Impact factor: 7.397

6.  Interferon-beta inhibits proliferation and progression through S phase of the cell cycle in five glioma cell lines.

Authors:  J I Garrison; M E Berens; J R Shapiro; S Treasurywala; G Floyd-Smith
Journal:  J Neurooncol       Date:  1996-12       Impact factor: 4.130

7.  Immunohistochemical identification of type II alternatively activated dendritic macrophages (RM 3/1+3, MS-1+/-, 25F9-) in psoriatic dermis.

Authors:  N Djemadji-Oudjiel; S Goerdt; V Kodelja; M Schmuth; C E Orfanos
Journal:  Arch Dermatol Res       Date:  1996-11       Impact factor: 3.017

8.  [Latest aspects in psoriasis pathogenesis].

Authors:  J C Prinz
Journal:  Hautarzt       Date:  2003-02-12       Impact factor: 0.751

9.  Regulatory T cells, a potent immunoregulatory target for CAM researchers: modulating tumor immunity, autoimmunity and alloreactive immunity (III).

Authors:  Aristo Vojdani; Jonathan Erde
Journal:  Evid Based Complement Alternat Med       Date:  2006-07-05       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.